S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Amicus Therapeutics Stock Forecast, Price & News

+0.03 (+0.28%)
(As of 12/1/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
2.36 million shs
Average Volume
2.88 million shs
Market Capitalization
$2.99 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Amicus Therapeutics logo

About Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.


Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $11.34
November 15, 2021 |  americanbankingnews.com
Stifel Nicolaus Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy
November 15, 2021 |  americanbankingnews.com
Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss
November 10, 2021 |  finance.yahoo.com
Is Amicus Therapeutics Headed for a Breakout?
November 3, 2021 |  stocknews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$260.89 million
Book Value
$1.10 per share


Net Income
$-276.85 million
Pretax Margin




Free Float
Market Cap
$2.99 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.10 out of 5 stars

Medical Sector

499th out of 1,392 stocks

Pharmaceutical Preparations Industry

232nd out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

How has Amicus Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FOLD stock has increased by 33.4% and is now trading at $10.74.
View which stocks have been most impacted by COVID-19

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Amicus Therapeutics

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. Amicus Therapeutics had a negative net margin of 81.17% and a negative trailing twelve-month return on equity of 84.62%. During the same quarter in the previous year, the company earned ($0.22) EPS.
View Amicus Therapeutics' earnings history

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $300 million-$315 million, compared to the consensus revenue estimate of $310.30 million.

What price target have analysts set for FOLD?

11 equities research analysts have issued 12-month price targets for Amicus Therapeutics' shares. Their forecasts range from $12.00 to $27.00. On average, they expect Amicus Therapeutics' share price to reach $16.56 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • John Francis Crowley, Chairman & Chief Executive Officer
  • Bradley Lewis Campbell, President, Chief Operating Officer & Director (LinkedIn Profile)
  • Daphne E. Quimi, Chief Financial Officer
  • Jill Weimer, Chief Science Officer
  • Patrik S. Florencio, Senior VP, Global Chief Compliance & Risk Officer

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (8.72%), BlackRock Inc. (7.35%), Morgan Stanley (4.19%), Deutsche Bank AG (2.67%), Janus Henderson Group PLC (2.53%) and Artal Group S.A. (2.51%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Deutsche Bank AG, BlackRock Inc., Two Sigma Advisers LP, Massachusetts Financial Services Co. MA, Voloridge Investment Management LLC, Longitude Cayman Ltd., and Primecap Management Co. CA. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Artal Group S.A., Janus Henderson Group PLC, Nordea Investment Management AB, BioImpact Capital LLC, Sphera Funds Management LTD., Two Sigma Investments LP, and Alliancebernstein L.P.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $10.74.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $2.99 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276.85 million in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 483 workers across the globe.

When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at [email protected], or via fax at 609-662-2001.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.